Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
9.07
-1.68 (-15.63%)
At close: Apr 28, 2026, 4:00 PM EDT
9.00
-0.07 (-0.77%)
After-hours: Apr 28, 2026, 5:59 PM EDT
Artiva Biotherapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Artiva Biotherapeutics stock have an average target of 18.67, with a low estimate of 15 and a high estimate of 23. The average target predicts an increase of 105.84% from the current stock price of 9.07.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 11, 2026.
Analyst Ratings
The average analyst rating for Artiva Biotherapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +98.46% | Mar 11, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $15 | Strong Buy | Maintains | $12 → $15 | +65.38% | Nov 12, 2025 |
| Wedbush | Wedbush | Buy Maintains $18 → $23 | Buy | Maintains | $18 → $23 | +153.58% | Oct 17, 2025 |
| Needham | Needham | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +98.46% | Oct 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +32.30% | Jun 11, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.49
from -3.43
EPS Next Year
-2.89
from -3.49
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.64 | -1.55 | |||
| Avg | -3.49 | -2.89 | |||
| Low | -4.10 | -4.21 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.